{"id":"https://openalex.org/W2947930698","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.9568","title":"Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI).","display_name":"Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI).","publication_year":2019,"publication_date":"2019-05-20","ids":{"openalex":"https://openalex.org/W2947930698","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.9568","mag":"2947930698"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2019.37.15_suppl.9568","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.9568","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.9568","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5086422682","display_name":"Fiona C. Taylor","orcid":"https://orcid.org/0000-0001-6474-4314","observed_orcids":["https://orcid.org/0000-0001-6474-4314"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fiona Taylor","raw_affiliation_strings":["Adelphi Values, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Adelphi Values, Boston, MA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017334876","display_name":"Meredith M. Regan","orcid":"https://orcid.org/0000-0002-2428-6109","observed_orcids":["https://orcid.org/0000-0002-2428-6109"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Meredith M. Regan","raw_affiliation_strings":["Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034365278","display_name":"Dirk Schadendorf","orcid":"https://orcid.org/0000-0003-3524-7858","observed_orcids":["https://orcid.org/0000-0003-3524-7858"]},"institutions":[{"id":"https://openalex.org/I62318514","display_name":"University of Duisburg-Essen","ror":"https://ror.org/04mz5ra38","country_code":"DE","type":"education","lineage":["https://openalex.org/I62318514"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Dirk Schadendorf","raw_affiliation_strings":["Department of Dermatology, University of Essen, Essen, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, University of Essen, Essen, Germany;","institution_ids":["https://openalex.org/I62318514"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052526230","display_name":"Michael B. Atkins","orcid":"https://orcid.org/0000-0003-3901-9924","observed_orcids":["https://orcid.org/0000-0003-3901-9924"]},"institutions":[{"id":"https://openalex.org/I2799903593","display_name":"Georgetown University Medical Center","ror":"https://ror.org/00hjz7x27","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799903593"]},{"id":"https://openalex.org/I4390039356","display_name":"Georgetown Lombardi Comprehensive Cancer Center","ror":"https://ror.org/035zrb927","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I184565670","https://openalex.org/I4390039356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael B. Atkins","raw_affiliation_strings":["Georgetown Lombardi Comprehensive Cancer Center, Washington, DC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Georgetown Lombardi Comprehensive Cancer Center, Washington, DC;","institution_ids":["https://openalex.org/I2799903593","https://openalex.org/I4390039356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103245475","display_name":"Rachael M Lawrance","orcid":"https://orcid.org/0000-0002-9499-8443","observed_orcids":["https://orcid.org/0000-0002-9499-8443"]},"institutions":[{"id":"https://openalex.org/I4210091464","display_name":"Adelphi Group (United Kingdom)","ror":"https://ror.org/00egpfv87","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210091464"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Rachael Lawrance","raw_affiliation_strings":["Adelphi Values, Bollington, Cheshire, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Adelphi Values, Bollington, Cheshire, United Kingdom;","institution_ids":["https://openalex.org/I4210091464"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013401197","display_name":"Alejandro Moreno\u2010Koehler","orcid":"https://orcid.org/0000-0003-2463-1643","observed_orcids":["https://orcid.org/0000-0003-2463-1643"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alejandro Moreno-Koehler","raw_affiliation_strings":["Adelphi Values, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Adelphi Values, Boston, MA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035574764","display_name":"Andriy Moshyk","orcid":"https://orcid.org/0000-0003-4895-7103","observed_orcids":["https://orcid.org/0000-0003-4895-7103"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andriy Moshyk","raw_affiliation_strings":["Bristol Myers-Squibb, Princeton, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers-Squibb, Princeton, NJ;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109110234","display_name":"Sumati A. Rao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sumati Rao","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, NJ;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084496300","display_name":"Corey Ritchings","orcid":"https://orcid.org/0000-0002-9240-9211","observed_orcids":["https://orcid.org/0000-0002-9240-9211"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Corey Ritchings","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, NJ;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113758960","display_name":"Srividya Kotapati","orcid":"https://orcid.org/0009-0008-7352-2885","observed_orcids":["https://orcid.org/0009-0008-7352-2885"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"SRIVIDYA KOTAPATI","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, NJ;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077284234","display_name":"Jennifer Lord\u2010Bessen","orcid":"https://orcid.org/0000-0001-8624-4556","observed_orcids":["https://orcid.org/0000-0001-8624-4556"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Lord-Bessen","raw_affiliation_strings":["Bristol Myers-Squibb, Princeton, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers-Squibb, Princeton, NJ;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011248803","display_name":"Jasmine I. Rizzo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jasmine I. Rizzo","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, NJ;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007052233","display_name":"David F. McDermott","orcid":"https://orcid.org/0000-0002-2675-5095","observed_orcids":["https://orcid.org/0000-0002-2675-5095","https://orcid.org/0000-0001-6978-0867"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David F. McDermott","raw_affiliation_strings":["Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA;","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5051430596","display_name":"Mark Ross Middleton","orcid":"https://orcid.org/0000-0003-0167-1685","observed_orcids":["https://orcid.org/0000-0003-0167-1685"]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Mark R. Middleton","raw_affiliation_strings":["Department of Oncology, University of Oxford, Oxford, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, University of Oxford, Oxford, United Kingdom;","institution_ids":["https://openalex.org/I40120149"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":10,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"37","issue":"15_suppl","first_page":"9568","last_page":"9568"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9160000085830688,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9160000085830688,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.046300001442432404,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10178","display_name":"Cancer survivorship and care","score":0.022299999371170998,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.8939999938011169},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.9509999752044678},{"id":"https://openalex.org/keywords/treatment-free-interval","display_name":"treatment-free interval","score":0.8320000171661377},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9760000109672546},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":1.0},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8090000152587891},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.7039999961853027},{"id":"https://openalex.org/keywords/symptom-burden","display_name":"symptom burden","score":0.8259999752044678},{"id":"https://openalex.org/keywords/eortc-qlq-c30","display_name":"EORTC QLQ-C30","score":0.8889999985694885},{"id":"https://openalex.org/keywords/eq-5d-3l","display_name":"EQ-5D-3L","score":0.9950000047683716},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.6710000038146973},{"id":"https://openalex.org/keywords/long-term-follow-up","display_name":"long-term follow-up","score":0.7269999980926514},{"id":"https://openalex.org/keywords/checkmate-067","display_name":"CheckMate 067","score":0.9039999842643738},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.6890000104904175},{"id":"https://openalex.org/keywords/functional-status","display_name":"functional status","score":0.3959999978542328},{"id":"https://openalex.org/keywords/health-related-quality-of-life","display_name":"health-related quality of life","score":0.6539999842643738}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9492335915565491},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.8198593854904175},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.770048975944519},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.7194427251815796},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6615115404129028},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5570364594459534},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.4900147020816803},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1874672770500183},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.13861462473869324},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0688927173614502},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2019.37.15_suppl.9568","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.9568","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.9568","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2947602393","https://openalex.org/W2244967365","https://openalex.org/W2513648362","https://openalex.org/W2516112263","https://openalex.org/W2944729926","https://openalex.org/W2753408607","https://openalex.org/W3169994009","https://openalex.org/W2636042323","https://openalex.org/W2470583568","https://openalex.org/W2499347045"],"abstract_inverted_index":{"9568":[0],"Background:":[1],"The":[2],"TFI":[3,27,66],"after":[4,47,155,163,176],"discontinuation":[5,50],"of":[6,45,73,193,216,321],"study":[7,69],"therapy":[8],"has":[9,28],"been":[10,30],"reported":[11,31,231],"to":[12,18,91,214,248,276,295,334,348,362],"be":[13,352],"longer":[14],"with":[15,51,368,371],"NIVO+IPI":[16],"compared":[17,361],"NIVO":[19,52,93,98,108,372],"or":[20,53,111,250,373],"IPI":[21,102,112],"alone,":[22],"but":[23,291],"QoL":[24,46,59,282,292,355],"during":[25,64,267,358],"the":[26,65,125,179,188,268,296,300,318,359],"not":[29],"in":[32,178,223,281,285,304,343,366],"advanced":[33],"melanoma":[34],"(MEL)":[35],"studies.":[36],"1-y":[37],"data":[38],"from":[39,61,226,244,346],"CheckMate":[40],"(CM)":[41],"067":[42,63],"showed":[43],"maintenance":[44],"treatment":[48],"(tx)":[49],"NIVO+IPI.":[54,374],"Here,":[55],"we":[56],"present":[57],"long-term":[58],"results":[60],"CM":[62,84],"(period":[67],"off":[68],"tx":[70,199,238,274],"and":[71,136,147,158,182,262],"free":[72],"subsequent":[74,217],"therapy),":[75],"based":[76],"on":[77],"an":[78],"updated":[79],"4-y":[80],"dataset.":[81],"Methods:":[82],"In":[83],"067,":[85],"945":[86],"pts":[87,195,253,271,367],"were":[88,122,230,242],"randomized":[89],"1:1:1":[90],"receive":[92],"3":[94,103,109,113,174],"mg/kg":[95,100,104,114],"+":[96,101,117],"placebo;":[97],"1":[99,151],"\u00d7":[105,115],"4,":[106],"then":[107],"mg/kg;":[110],"4":[116],"placebo.":[118],"Patient-reported":[119],"outcomes":[120],"(PRO)":[121],"collected":[123,168,212],"using":[124],"EORTC":[126,259],"QLQ-C30":[127,260],"(5":[128],"functional":[129,261],"domains,":[130],"9":[131],"symptoms,":[132],"global":[133],"health":[134],"status)":[135],"EQ-5D-3L":[137,165],"(utility":[138],"index,":[139],"visual":[140],"analog":[141],"scale)":[142],"at":[143,169,289,327],"baseline,":[144],"on-tx":[145,228,246,302,364],"visits,":[146],"follow-up":[148],"(FU)":[149],"visits":[150,172,330,350],"(FU1;":[152],"30":[153],"d":[154,162],"last":[156,227,245,301,363],"dose)":[157],"2":[159],"(FU2;":[160],"84":[161],"FU1).":[164],"was":[166,283,293,331,356],"also":[167],"survival":[170],"FU":[171,234,329,349],"every":[173,183],"mo":[175,185],"FU2":[177,251,316],"first":[180],"year":[181],"6":[184],"thereafter.":[186],"Within":[187],"PRO":[189,210,224,240,311,344],"analysis":[190],"population,":[191],"480":[192],"764":[194],"who":[196,254,272],"discontinued":[197,255,273],"protocol":[198],"(for":[200],"any":[201,257],"reason,":[202],"including":[203],"drug":[204],"toxicity;":[205],"n":[206],"=":[207],"155)":[208],"had":[209],"scores,":[211],"prior":[213],"initiation":[215],"anticancer":[218],"therapy,":[219],"evaluated.":[220],"Mean":[221],"changes":[222],"scores":[225,241,312,345],"visit":[229,247,303],"for":[232,252,256,317,323,340],"each":[233],"visit.":[235],"Results:":[236],"Across":[237],"arms,":[239],"maintained":[243,357],"FU1":[249],"reason.":[258],"symptom":[263],"scales":[264],"remained":[265,313],"stable":[266,314],"TFI.":[269],"Among":[270],"due":[275,333],"toxicity,":[277],"clinically":[278],"meaningful":[279],"deterioration":[280],"observed":[284],"a":[286],"few":[287],"subscales":[288],"FU1,":[290],"restored":[294],"same":[297],"level":[298],"as":[299],"all":[305],"except":[306],"one":[307],"subscale":[308],"by":[309],"FU2.":[310],"beyond":[315],"EQ-5D-3L,":[319],"regardless":[320],"reason":[322],"discontinuation.":[324],"Data":[325],"interpretation":[326],"later":[328],"limited":[332],"smaller":[335],"sample":[336],"sizes.":[337],"Sensitivity":[338],"analyses":[339],"mean":[341],"change":[342],"randomization":[347],"will":[351],"presented.":[353],"Conclusions:":[354],"TFI,":[360],"visit,":[365],"MEL":[369],"treated":[370]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2019-06-07T00:00:00"}